ClinicalTrials.Veeva

Menu

The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine

J

Jiangsu Provincial Center for Disease Control and Prevention

Status and phase

Completed
Phase 4

Conditions

Influenza

Treatments

Biological: Intranasal Influenza Live Attenuated Vaccine

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT06609811
JSJKYMS001

Details and patient eligibility

About

This is a single-center, randomized, open-label trial designed to explore the interaction between mucosal microbiota colonization in the nasal cavity and gut and the immune response to an intranasal live attenuated influenza vaccine (LAIV). The study plans to enroll 200 children and adolescents aged 6-17 years, with approximately 50% in the 6-11 years age group and 50% in the 12-17 years age group. Participants and their guardians must be able and willing to comply with the clinical trial protocol and provide informed consent. Eligible participants will be randomly assigned in a 1:1 ratio, stratified by age groups, to either the immediate vaccination group or the delayed vaccination group. Nasal swabs will be collected for all participants of both the immediate vaccination group or the delayed vaccination group after randomization for the detection of nasal and gut microbiota. Then, the immediate vaccination group will receive one dose of 0.2 mL of LAIV 28 days after randomization, while the delayed vaccination group will receive one dose of 0.2 mL of LAIV 56 days after randomization. Blood and mucosal samples (nasal stool) will be collected on the day before vaccination and on 28 days after vaccination for humoral and mucosal immunogenicity analysis. Moreover, the occurrence of adverse events within 28 days after vaccination will be collected.

Enrollment

200 patients

Sex

All

Ages

6 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Individuals aged 6-17 years.
  2. Volunteers and their guardians are able and willing to comply with the requirements of the clinical trial protocol and sign the informed consent form.

Exclusion criteria

  1. Allergy to any component of the vaccine product, including eggs, excipients, or gentamicin sulfate.
  2. Individuals with acute illnesses, severe chronic illnesses, acute exacerbations of chronic illnesses, or fever.
  3. Pregnant or lactating women.
  4. Individuals with Leigh syndrome who are receiving treatment with aspirin or aspirin-containing medications.
  5. Individuals with immunodeficiency, immunosuppression, or those undergoing immunosuppressive therapy.
  6. Individuals with uncontrolled epilepsy, other progressive neurological disorders, or a history of Guillain-Barré syndrome.
  7. Individuals with rhinitis or asthma.
  8. Individuals with a personal or family history of seizures, chronic diseases, epilepsy, or allergic tendencies.
  9. Individuals who have received immunoglobulin injections within the last 3 months prior to vaccination.
  10. Individuals who have used other live attenuated vaccines within 1 month prior to vaccination.
  11. Individuals planning to use antiviral drugs for influenza within 48 hours before or 2 weeks after vaccination.
  12. Individuals planning to use any other intranasal medication within 2 days after vaccination.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

The immediate vaccination group.
Experimental group
Description:
Participants are assigned to receive one dose of 0.2 mL of intranasal live attenuated influenza vaccine immediately (Day 0)
Treatment:
Biological: Intranasal Influenza Live Attenuated Vaccine
Biological: Intranasal Influenza Live Attenuated Vaccine
The delayed vaccination group
Experimental group
Description:
Participants are assigned to receive one dose of 0.2 mL of intranasal live attenuated influenza vaccine after a delay (Day 28).
Treatment:
Biological: Intranasal Influenza Live Attenuated Vaccine
Biological: Intranasal Influenza Live Attenuated Vaccine

Trial contacts and locations

1

Loading...

Central trial contact

Jing-Xin Li, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems